XML 11 R2.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 10,008 $ 10,743
Available-for-sale investments 56,505 67,944
Other receivables 477 873
Prepaid expenses 586 677
Total current assets 67,576 80,237
Restricted cash 1,805 2,235
Property and equipment, net 4,237 4,263
Operating lease, right-of-use assets 5,441 5,524
Financing lease, right-of-use assets 447 596
Other assets 148 148
Total assets 79,654 93,003
Current liabilities:    
Accounts payable 2,755 3,891
Accrued expenses 7,458 9,791
Current portion of operating lease liability 890 836
Current portion of financing lease liability 596 630
Total current liabilities 11,699 15,148
Long-term operating lease liability, net of current portion 10,063 10,308
Long-term financing lease liability, net of current portion 151 259
Commitments and contingencies (Note 4)
Stockholders’ equity:    
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of March 31, 2026 (unaudited) and December 31, 2025, respectively; no shares issued or outstanding as of March 31, 2026 (unaudited) and December 31, 2025
Common stock, $0.001 par value per share; 170,000,000 authorized shares as of March 31, 2026 (unaudited) and December 31, 2025, issued and outstanding shares -- 98,051,212 as of March 31, 2026 (unaudited) and 98,031,104 as of December 31, 2025 98 98
Additional paid-in capital 674,861 673,554
Accumulated other comprehensive loss (70) (8)
Accumulated deficit (616,955) (606,164)
Total aTyr Pharma stockholders’ equity 57,934 67,480
Noncontrolling interest in Pangu BioPharma Limited (193) (192)
Total stockholders' equity 57,741 67,288
Total liabilities and stockholders’ equity $ 79,654 $ 93,003